Aventiv Research Inc

1. Pfizer Inc. $11,340,390 546 payments
2. AbbVie, Inc. $2,037,191 190 payments
3. Moderna TX, Inc. $925,639 635 payments
4. Emergent BioSolutions Inc. $645,971 748 payments
5. GlaxoSmithKline, LLC. $424,473 61 payments
6. BioNTech SE $405,053 61 payments
7. Sanofi Pasteur Inc. $373,073 34 payments
8. Merck Sharp & Dohme Corporation $341,297 8 payments
9. Regeneron Pharmaceuticals, Inc. $308,166 74 payments
10. Akebia Therapeutics Inc $265,196 244 payments

1. A Phase 123 Placebocontrolled Randomized Observerblind Dosefinding Study to Evaluate the Safety Tolerability Immunogenicity and Efficacy of Sarscov2 Rna Vaccine Candidates Against Covid19 in Healthy Adults $5,004,495 90 payments
2. Phase 1 Openlabel Dosefinding Study to Evaluate Safety Tolerability and Immunogenicity and Phase 23 Placebocontrolled Observerblinded Safety Tolerability and Immunogenicity Study of A Sarscov2 Rna Vaccine Candidate Against Covid19 in Healthy Children and Young Adults $2,574,864 63 payments
3. A Phase 3 Randomized Observerblinded Study to Evaluate the Efficacy Safety Tolerability and Immunogenicity of A Modified Rna Vaccine Against Influenza Compared to Licensed Inactivated Influenza Vaccine in Healthy Adults 18 Years of Age Or Older $816,962 71 payments
4. A Study to Assess Adverse Events and Change in Disease Activity of Intramuscular AGN-151586 Injection in Adult Participants With Glabellar Lines $779,449 22 payments
5. A Phase 3 Study to Evaluate the Efficacy Immunogenicity and Safety of Respiratory Syncytial Virus RSV Prefusion F Subunit Vaccine in Adults $644,797 34 payments
6. A Phase 3 Master Protocol to Evaluate Additional Doses of Bnt162b2 in Healthy Individuals Previously Vaccinated With Bnt162b2 $636,132 34 payments
7. VELOCITY: An Anthrax Vaccine Clinical Study $613,210 747 payments
8. A Study to the Assess the Change in Condition and Adverse Events of OnabotulinumtoxinA X Injection in Adult Participants With Glabellar Lines $501,824 25 payments
9. Bnt162-17 $405,053 61 payments
10. A Phase 3, Randomized, Double-blind, Active Comparator-controlled Clinical Study to Evaluate the Safety, Tolerability, and Immunogenicity of V116 in Pneumococcal Vaccine na Adults $331,545 6 payments

1. Patient care $50,212 9 payments
2. Other $42,437 50 payments

Only reported on some payments, and a payment can report more than one category, so these amounts overlap.